Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HIV Treatment Options For Patients Improve In Japan

This article was originally published in PharmAsia News

Executive Summary

Japan Tobacco brings Stribild home after U.S./EU launches by Gilead. Johnson & Johnson reduces patient burden with higher dose Prezista.

You may also be interested in...

The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild

With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.

Ranbaxy’s GMP Woes Puts Spotlight On Daiichi Sankyo Due Diligence

Whether Daiichi Sankyo will be able to claim damages from Ranbaxy’s former owners will depend on what Daiichi Sankyo knew before the acquisition, and its chances of proving misrepresentation may be slim.

Are Novartis’ Advertising Charges In Japan The Tip Of The Iceberg?

Prosecutors are looking into allegations of exaggerated advertising, but a bribery investigation may be the real aim for authorities.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts